ArticleNutrition journal2026
Multimodal intervention for sarcopenia in nasopharyngeal carcinoma patients undergoing definitive treatment: a pilot randomized controlled trial protocol.
Article in Nutrition journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThis protocol describes a pilot randomized controlled trial (RCT) designed to assess the feasibility of a multidisciplinary, multimodal intervention for sarcopenia prevention in patients with nasopharyngeal carcinoma (NPC) undergoing concurrent chemoradiotherapy (CCRT). The intervention was developed using the Medical Research Council (MRC) framework and incorporates personalized immunonutrition, structured exercise, side effect management, behavior monitoring, and guidance. This pilot trial aims to evaluate the feasibility of implementing a multimodal intervention model in this patient population.
methodsThis study will be a single-site RCT including 30 patients with NPC undergoing definitive treatment. The trial will be conducted from September 2025 to May 2026 in Ningxia, China. Patients will be randomly assigned to either the intervention or control group. The intervention integrates head and neck and gastrointestinal cluster symptom management, immunonutrition management, and exercise based on the Theory of Planned Behavior. The primary outcome is feasibility, assessed through acceptability, demand, fidelity, and practicality. Secondary outcomes include changes in skeletal muscle index, sarcopenia prevalence, body composition, composite biomarkers (Global Immune-Nutrition-Inflammation Index [GINI], Hemoglobin–Albumin–Lymphocyte–Platelet Score [HALP], and Prognostic Nutritional Index [PNI]), symptom burden (Head and Neck Symptom Checklist), nutritional status (Patient-Generated Subjective Global Assessment [PG-SGA]), and adherence to exercise and dietary interventions. Exploratory outcomes include behavior change mechanisms assessed using a Theory of Planned Behavior–based questionnaire. DISCUSSION: This pilot study is designed to evaluate the feasibility of implementing a comprehensive multimodal intervention for sarcopenia in NPC patients undergoing CCRT. The outcomes will provide preliminary evidence to guide the design of future large-scale RCTs and advance multidisciplinary care models for sarcopenia management in oncology.
trial registrationUMIN Clinical Trials Registry, UMIN000059146.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.